Novo Nordisk A/S: Resolutions from the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 19 March 2015 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted:

 

Financial year 2014 and 2015

• The Company's audited Annual Report 2014.
• The remuneration of the Board of Directors for 2014 and the level for 2015.
• Distribution of profit according to the adopted Annual Report 2014. The dividend will be DKK 5.00 per A and B share of DKK 0.20.

Elections 

• Re-election of Göran Ando as chairman and Jeppe Christiansen as vice chairman of the Board of Directors. 
• Re-election of Bruno Angelici, Liz Hewitt, and Thomas Paul Koestler as members of the Board of Directors. 
• Election of Sylvie Grégoire, Eivind Kolding and Mary Szela as new members of the Board of Directors.
• Re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as the Company's auditor. 

Shares and capital

• Reduction of the Company's B share capital by cancellation of part of the Company's own holding of B shares. The Company's B shares are reduced by DKK 10,000,000 from DKK 422,512,800 to DKK 412,512,800. 
• Authorisation to the Board of Directors until the next Annual General Meeting to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital. 

Other

• Amendment to the Articles of Association to allow distribution of extraordinary dividend.
• Revised Remuneration Principles.

Further information

Media:
Mike Rulis	[phone]	[e-mail] (mailto:[e-mail])
Ken Inchausti (US)	[phone]	[e-mail] (mailto:[e-mail])
Investors:
Kasper Roseeuw Poulsen	[phone]	[e-mail] (mailto:[e-mail])
Daniel Bohsen	[phone]	[e-mail] (mailto:[e-mail])
Melanie Raouzeos	[phone]	[e-mail] (mailto:[e-mail])
Frank Daniel Mersebach (US)	[phone]	[e-mail] (mailto:[e-mail])

Company announcement No 19 / 2015

Company announcement No 19 / 2015 (http://hugin.info/2013/R/1904763/677683.pdf)

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#1904763